摘要
目的:评价替考拉宁治疗G^+菌感染的疗效和安全性。方法:采用随机对照及开放试验,以万古霉素为对照。完成病例60例,其中试验组30例,替考拉宁0.2～0.4g,qd,静脉滴注;对照组30例,万古霉素0.5g,tid,静脉滴注。疗程均为7～14d。结果:试验组痊愈率、有效率、细菌清除率分别为50％,80％和83.3％,对照组分别为46.7％,76.7％和76.7％,2组差异无显著性。不良反应发生率分别为10％和13.3％,2组差异亦无显著性。结论:替考拉宁治疗G^+菌感染安全有效。
Objective:To study the safety and efficacy of teicoplanin in treatment of gram-positive bacterial infections. Methods: In the randomized, controlled and opened clinical trial, 60 patients were equally divided to receive once daily dose of 0.2-0.4g teicoplanin given by infusion for 7-14d or 3 times daily dose of 0. 5g intravenous vancomycin for 7-14d. Results:The cure rate, total effective rate and bacterial clearance rate were 50 % , 80 % , and 83.3% respectively for teicoplanin group and were 46.7% ,76.7% and 76.7% respectively for control group. 10% adverse drug reactions occurred in teicoplanin group and 13.3% in vancomycin group.Conclusion:Teicoplanin seems to be a highly effective and safe agent for treatment of gram-positive bacterial infections.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2003年第12期1041-1043,共3页
Chinese Journal of New Drugs
关键词
替考拉宁
万古霉素
G^+菌
teicoplanin
vancomycin
gram-positive bacterial
